Drug treatment of obsessive-compulsive disorder (OCD): Long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs)

Psychopharmacology Bulletin

Volumn 32, Issue 1, 1996, Pages 167-173

  Ravizza, Luigi ^b   Barzega, Giulio ^b   Bellino, Silvio ^b   Bogetto, Filippo ^b   Maina, Giuseppe ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b NONE

Author keywords

clomipramine; drug discontinuation; maintenance treatment; obsessive compulsive disorder; SSRI

Indexed keywords

CLOMIPRAMINE; FLUOXETINE; FLUVOXAMINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OBSESSION; ONSET AGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE;

ADULT; CLOMIPRAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOXETINE; FLUVOXAMINE; FOLLOW-UP STUDIES; HUMANS; MALE; OBSESSIVE-COMPULSIVE DISORDER; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS;

EID: 0029889666     PISSN: 00485764     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (19)

1. American Psychiatric Association. DSM-III-R: Diagnostic and Statistical Manual of Mental Disorders. 3d ed., revised. Washington, DC: The Association, 1987.
2. Fontaine, R, and Chouinard, G. Fluoxetine in the long-term treatment of obsessive compulsive disorder. Psychiatr. Ann. 19:88-91, 1989.
3. Goodman, W; Price, L; Rasmussen, S; Mazure, C; Fleischmann, RL; Hill, CL; Heninger, GR; and Charney, DS. The Yale-Brown Obsessive Compulsive Scale (Y-BOCS): Part I. Development, use and reliability. Arch. Gen. Psychiatry 46:1006-1011, 1989a.
4. Goodman, W; Price, L; Rasmussen, S; Mazure, C; Delgado, P; Heninger, GR; and Charney, DS. The Yale-Brown Obsessive Compulsive Scale (Y-BOCS): Part II. Validity. Arch. Gen. Psychiatry 46:1012-1016, 1989b.
5. Greist, JH; Jefferson, JW; Kobak, KA; Katzelnick, DJ; and Serlin, RC. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis. Arch. Gen. Psychiatry 52(1):53-60, 1995.
6. Guy, W, ed. ECDEU Assessment Manual for Psychopharmacology, revised. DHEW Pub. No. (ADM)76-338. Rockville, MD: National Institute of Mental Health, 1976.
7. Hamilton, M. A rating scale for depression. J. Neurol. Neuro-Surg. Psychiatry 23:56-62, 1960.
8. Leonard, HL; Swedo, SE; Lenane, MC; Rettew, DC; Cheslow, DL; Hamburger, SD; and Rapoport, JL. A double-blind substitution during long-term clomipramine treatment in children and adolescents. Arch. Gen. Psychiatry 48:922-927, 1991.
9. Montgomery, SA. Pharmacological treatment of obsessive compulsive disorder. In: Hollander, E; Zohar, J; Marazziti, D; and Olivier, B, eds. Current Insights in Obsessive Compulsive Disorder. New York: John Wiley & Sons, 1994. pp. 215-226.
10. National Institute of Mental Health. Special feature: Rating scales and assessment instruments for use in pediatric psychopharmacology research. Psychopharmacol. Bull. 21(4), 1985.
11. Pato, MT. When to discontinue pharmacologic treatment. In: Jenike, MA; Baer, L; and Minichiello, WE, eds. Obsessive-Compulsive Disorders: Theory and Management. St. Louis, MO: Mosby Year Book, 1990. pp. 312-322.
12. Pato, MT; Hill, JL; and Murphy, PL. A clomipramine dosage reduction study in the course of long-term treatment of obsessive compulsive disorder patients. Psychopharmacol. Bull. 26:211-214, 1990.
13. Pato, M; Murphy, DL; and DeVane, CL. Sustained plasma concentrations of fluoxetine and/or norfluoxetine four and eight weeks after fluoxetine discontinuation. J. Clin. Psychopharmacol. 11:224-225, 1991.
14. Pato, MT, and Zohar, J. Current Treatments of Obsessive-Compulsive Disorder. Washington, DC: American Psychiatric Press, 1991.
15. Pato, MT; Zohar-Kadouch, R; Zohar, J; and Murphy, DL. Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder. Am. J. Psychiatry 145:1521-1525, 1988.
16. Piccinelli, M; Pini, S; Bellantuono, C; and Wilkinson, G. Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review. Br. J. Psychiatry 166:424-443, 1995.
17. Rasmussen, SA; Eisen, JL; and Pato, MT. Current issues in the pharmacologic management of obsessive compulsive disorder. J. Clin. Psychiatry 54(6, Suppl.):4-9, 1993.
18. Ravizza, L; Barzega, G; Bellino, S; Bogetto, F; and Maina, G. Predictors of response and long-term treatment of obsessive-compulsive disorder. In: Darcourt, G; Mendlewicz, J; Racagni, G; and Brunello, N, eds. Current Therapeutic Approaches to Panic and Other Anxiety Disorders. Basel: S. Karger, 1994. pp. 164-170.
19. Tollefson, GD; Birkett, M; Koran, L; and Genduso, L. Continuation treatment of OCD: Double-blind and open-label experience with fluoxetine. J. Clin. Psychiatry 55(10, Suppl.):69-76, 1994.